Solitary fibrous tumor of the scrotum: a case report and review of the literature

Tsung-Hsin Chang1,2, Marcelo Chen1,2 and Chih-Chiao Lee1,2*

Abstract

Background: Solitary fibrous tumor (SFT) is a rare soft tissue tumor originally reported in the pleura. Although it has been reported in various extra-pleural sites, the occurrence of SFT in the scrotum is extremely rare. Herein, we present a 48-year-old man who had scrotal SFT. There are very few reported cases of genitourinary SFTs, this is only the fifth report of SFT of the scrotum in the English medical literature.

Case presentation: In this study, we report on a 48-year-old man who presented with a 5 × 8 cm scrotal mass between his testes. Physical examination revealed a 4.7 × 8.5 cm lobulated tumor mass located between his testicles. Surgical excision of the tumor with scrotal approach was done and pathology reported a SFT. The patient was alive without tumor recurrence or distant metastasis during ongoing follow-up for 9 months post-operatively.

Conclusion: Scrotal SFTs are very rare and only five cases have been reported in English literature to date. Treatment often involves surgical resection, and a definite diagnosis is made with the help of immunohistochemistry. The current general consensus for the management of SFTs is long-term follow-up after surgical excision of the tumor.

Keywords: Solitary fibrous tumor, Scrotum

Background

Solitary fibrous tumor (SFT) is a rare mesenchymal spindle cell neoplasm usually originating from the pleura. It was first described by Klemperer and Rabin in 1931 [1] and has since been reported in various extra-pleural sites. However, reports of urogenital SFTs are extremely rare and only a few cases of scrotal SFTs have been reported [2–9]. Treatment usually involves enucleation and excision of the tumor. Diagnosis is made with the help of immunohistopathological examinations. We hereby report the clinical and pathological characteristics of scrotal SFT.

Case presentation

A 48-year-old male presented with a slow-growing right scrotal mass for the past 2 years. This clearly-demarcated nodular mass was located over the middle-to-right side of the scrotum. The tumor had rapidly increased in size over the past 3 months, but there was no obvious pain or other symptoms. Physical examination revealed a 4.7 × 8.5 cm lobulated tumor mass located between his testicles, non adherent to the scrotum. It was freely movable with elastic consistency on palpation. The penis and testicles were normal in appearance. Testis tumor markers were all normal [alpha-fetoprotein (AFP) = 2.87 ng/mL; beta-human chorionic gonadotrophin (β-HCG) < 0.6 mIU/mL].

Scrotal ultrasonography showed a hypoechoic extra-testicular mass with clear contours and rich blood flow. Computed tomography (CT) showed a hypervascularized lobulated mass (4.7 × 8.5 cm) with contrast media enhancement in the midline of the scrotum (Fig. 1). He then underwent tumor excision via scrotal approach since the tumor did not seem originated from testicular or spermatic cord and the location of the tumor was superficial. A midline raphe incision was made and carry down to the tunica vaginalis. The tumor mass was not adherent to the surrounding tissues or testicles, it was a separated mass with clear margin that could be...
easily dissected with blunt dissection method. The tumor was completely excised after ligating the main feeding vessels.

The resected specimen consisted of three lobulated and contiguous firm tumors, measuring $7.5 \times 6.3 \times 3.8$ cm in size and weighing 76.5 g in total (Fig. 2a). Cut section of the tumor showed a well-defined, lobulated, whitish and firm tumor with some mucinous components (Fig. 2b). Microscopically, it was a hypercellular tumor with a vaguely fascicular growth pattern forming a patternless growth architecture (Fig. 3a) with minimal nucleare atypia rate and a mitotic count $< 4$ per 10 high power field. A few thin-walled, branching "staghorn appearance" vessels were also present in the tumor (Fig. 3b). The tumor cells had an ovoid to short spindle shape with indistinct borders and dispersed chromatin within vesicular nuclei. Immunohistochemically, the tumor cells were positive for STAT-6 (nuclear expression) (Fig. 4a) and CD34 (Fig. 4b), and negative for actin, desmin, CD117 and DOG-1. Based on the morphology and immunohistochemical studies, the diagnosis of SFT was made. The patient was alive without tumor recurrence or distant metastasis during ongoing follow-up for 9 months post-operatively with semi-annual CTs.

**Discussion and conclusions**

SFT is a soft tissue tumor which usually presents as a firm, grey-to-white colored, well-circumscribed solid mass. It was first reported by Klemperer and Rabin in 1931 in the pleura. Although the disease most commonly occurs in the pleura, extra-thoracic SFTs have been reported in many sites including the head and neck [10], intracranial and spinal cord meninges [11], eyes [12], thyroid [13], larynx [14], gastrointestinal system [15–17], genitourinary tract [18–20], pelvis [21] and soft tissue [22]. The most common extra-pleural locations are the meninges, followed by subcutaneous tissues of the lower limbs, the retroperitoneum, and the orbit [23]. Extra-pleural SFTs share similar histological features with pleural SFTs [23].

There are very few reported cases of genitourinary SFTs, and SFTs of the scrotum or para-testicular
SFTs are extremely rare (Table 1). This is only the fifth report of SFT of the scrotum in the English medical literature, and the only report with three documented connected nodules, which is different from the usual appearance of a SFT with a single solitary nodule.

The diagnosis of extra-pleural SFTs is challenging and relies on its clinical manifestations or imaging studies. Differential diagnosis of SFTs arising from para-testicles soft tissues can be challenging since it can show great similarity to those spindle cell fibroblastic associated tumors, such as angiomyolipomas, leimyoma, fibrosarcomas and gastrointestinal stromal tumors (GIST). Therefore, immunohistochemistry plays an important role in the diagnosis of SFTs. Traditionally, CD34 and BLC-2 have a high sensitivity for SFTs, and CD34 is only absent in 5 to 10% of typical SFTs [24]. BCL-2 is seen in almost all cases of SFTs [25, 26]. However, these traditional markers are not specific to SFTs, and they may also be present in many other mesenchymal tumors mimicking SFTs, which may lead to confusion and uncertainty in the diagnosis. In 2013, Chmelecki et al. [27] and Robinson et al. [28] reported that NAB2-STAT6, a new fusion gene expression present in the vast majority of SFTs, can be used as a unique molecular marker for the diagnosis of SFTs. Subsequent reports have demonstrated that the immunohistochemical nuclear expression of STAT6 in SFTs can distinguish SFTs from other histologic mimics, and that it can be used as a diagnostic tool [29–31]. Thus, in current clinical settings, the diagnosis of SFTs can be made if STAT6 nuclear expression, CD34 and BCL-2 are all strongly positive. NAB2-STAT6 fusion genetic tests may not be necessary for the diagnosis of SFTs under such circumstances.

SFTs are usually considered to follow a benign clinical course with a low potential of malignant change, and surgical excision of the lesion is usually...
sufficient. There were no current consensus on how the surgical approach should be done. Since SFTs usually present as a low-malignant potential tumor, both inguinal and scrotal approach for tumor exploration and excision had been reported. However, malignant pathology and behavior have been described in about 20% of SFTs [32]. The diagnosis of malignant SFT is based on pathologic examinations of histological features. The presence of hypercellularity, infiltrative margin growth, > 4 mitotic counts per 10 high-power fields and nuclear atypia have been reported to be histological malignant components [29, 32, 33]. In a multicenter study including 81 patients with surgically treated SFTs, patients with histologically malignant SFTs had higher local recurrence rates and higher incidence of metastasis [34]. Positive surgical margins, tumor size > 10 cm, and the presence of a high mitotic rate have been reported to be significantly correlated with a higher incidence of metastasis and worse overall survival.

In conclusion, SFT is a rare mesenchymal spindle cell neoplasm originally reported in the pleura, but it can be found in various sites throughout the body. Scrotal SFTs are very rare and only five cases have been reported to date. Treatment often involves surgical resection, and a definite diagnosis is made with the help of immunohistochemistry, especially the nuclear expression of STAT6. SFTs are often benign but there is a slight chance of malignancy. Patients with histologically malignant features may have worse prognosis. The current general consensus for the management of SFTs is long-term follow-up after surgical excision of the tumor. In our experience, we performed surgical resection of the tumor via scrotal approach without additional interventions. 6-month follow-up with CT scan was conducted, we will continue the follow-up of this case to monitor long-term outcome of this rare disease.

**Abbreviation**

CT: Computed tomography; SFT: Solitary fibrous tumor

**Acknowledgements**

Not applicable.

**Authors’ contributions**

THC made contributions to the acquisition of history, image and wrote the manuscript. CCL performed the treatment, and reviewed the manuscript to give clinical opinions. MC made supervision and helped reviewing the manuscript. All the authors read and approved the final manuscript.

**Funding**

None to declare.

**Availability of data and materials**

Records and data pertaining to this case are in the patient’s secure medical records in Mackay Memorial Hospital.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Informed consent was obtained in both written and verbal format from the patient to publish this case report and any accompanying images.

**Competing interests**

The authors declare that they have no competing interests.

### Table 1 Reported cases of paratesticular SFTs

| Reference       | Year | Age | Initial presentation | Location | Tumor size (cm) | Treatment | Recurrence/ Follow-up time | Immuno-histochemical features |
|-----------------|------|-----|----------------------|----------|----------------|-----------|---------------------------|-------------------------------|
| Marquez MA et al. [2] | 2001 | 67  | Paratesticular mass  | NA       | 9              | Surgical excision | NA            | CD34+, Vimentin+, Actin-, S100-, Keratin- |
| Garcia TM et al. [3] | 2006 | 22  | Pain                 | Left tunica vaginalis testis | 3         | Surgical excision with intraoperative biopsy | None/12 months | NA |
| Gutierrez-Diaz CM et al. [5] | 2011 | 53  | NA                   | Paratesticular | NA      | NA              | NA            | CD34+, BCL-2 +, vimentin+ |
| Lee GE et al. [4] | 2011 | 61  | Slow growing mass   | Left scrotal sac | 5 × 4     | Surgical excision | NA/NA         | CD34+ |
| Barazani Y et al. [6] | 2012 | 26  | Painless firm mass  | Left scrotum | 6.1 × 5.5 × 4.3 | Inguinal exploration | None/NA | CD34+, BCL-2 +, SMA -, Desmin-, S100- |
| Hu SB et al. [7] | 2014 | 31  | Left inguinoscrotal swelling | Left spermatic cord | 3 × 2 | Inguinal exploration | None/25 months | CD99+, Bcl-2+, Partial CD34+, Focal S-100+, SMA+, CD68- |
| Zhou YH et al. [8] | 2015 | 61  | Slow growing mass   | Left scrotum | 4 × 4.5 × 5 | Surgical excision (Inguinal) | None/6 months | CD34+, CD99+, Vimentin+, CD117, S100+, SMA-, Desmin-, CD68- |
| Zhao XY et al. [9] | 2017 | 77  | Painless mass       | Left scrotum | 11x9x8 | Surgical excision | None/18 months | CD34+, CD99+, STAT6+ |

NA not available, CD cluster of differentiation, STAT6, activator of transcription 6
References

1. Kemapeter P, Coleman BR. Primary neoplasms of the pleura. A report of five cases. Am. J. Ind. Med. 1992;22(1):1–31.
2. Márquez AM, Vicioso LR, Castro AL, Casals JS, Alcázar JR, Matilla AV. Parasternal solitary fibrous tumor. J Archivos Espanoles de Uologia. 2001; 54(7):176–8.
3. García MT, Beltrán JA, Santolaya IG, Carrascosa VL, Tarín MP, CJDJLAedu S. Solitary fibrous tumor of the tunica vasculosa testis. Arch Esp Urol. 2006; 59(2):180–9.
4. Lee GE, Rha SE, Byun JY, Lee K, SWJJoUiM K. Parasternal solitary fibrous tumor: a rare cause of a hypervascular extratesticular mass. J Ultrasound Med. 2011;30(2):279–81.
5. Ceballos MEG-D, Hernández-Solís A, Cruz-Ortiz H, González-Atencio Y, Cicero-Salido RJCC. Solitary fibrous tumor: clinicopathological study of 16 cases. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2011;79387–93.
6. Barazani Y, Taren B. Rare case of paratesticular solitary fibrous tumor (Ilopomatous hemangioepiroytoma). Can Urol Assoc J. 2012;6(3):E131–3.
7. Hu S, Yi L, Yang L, Wang Y. Solitary fibrous tumor of the spermatic cord: a case report and literature review. Exp Ther Med. 2015;9(1):551–55.
8. Zhou Y, Gong G, Tang Y, Tang J, Gan Y, Yijie D. Pathology e: Parasternal solitary fibrous tumor: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(3):3358.
9. Zhao XY, Zeng M, Yang QY, Jing CP, Zhang Y. Scrotal solitary fibrous tumor: a case report and review of literature. Medicine (Baltimore). 2017; 96(48)e8854.
10. Smith SC, Gooding WE, Patel RM, Harms PW, McDaniel AS, Canadian Academy of Pathology, Inc. 2011;79:387–93.
11. Bouvier C, Métellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, RJTAjosp K. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol. 2014;38(4):552–9.
12. Petito C, Abecia A, Moulin A, Hamedani M. Ocular adnexal (orbital) solitary fibrous tumor: nuclear STAT6 expression and literature review. Graefe’s Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(9):1609–17.
13. Ghasemi-Rad M, Wang KY, Jain S, Lincoln CM. Solitary fibrous tumor of the thyroid: a case report with review of literature. Clin Imaging. 2015;39(3):224–30.
14. Petrovic A, Oberic A, Moulin A, Hamedani M. Rare neoplasm mimicking gastrointestinal stromal tumor of the small intestine: a case report and review of literature. Anticancer Res. 2017;37(6):3093–9.
15. Zhang X, Cheng H, Bao Y, Tang F, Wang Y. diagnostic value of STAT6 expression in thyroid lesions. Acta Endocrinol (Copenhagen). 2018;218(2):164–214.
16. Usu H, Ceballos MEG-D, Hernández-Solís A, Cruz-Ortiz H, González-Atencio Y, Cicero-Salido RJCC. Solitary fibrous tumor: nuclear STAT6 expression and literature review. Graefe’s Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(9):1609–17.
17. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick J. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27(3):390–404.
18. Zhang X, Cheng H, Bao Y, Tang F, Wang Y. diagnostic value of STAT6 expression in thyroid lesions. Acta Endocrinol (Copenhagen). 2018;218(2):164–214.
19. Quaglia A, Cooper A, Enzinger FM, Coit DG. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 1999;86(1):58–65.
20. Li S, Kowalski D, Beck SD, Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ, Brennan MF, Coit DG. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057–68.
21. England DM, Holzholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13(8):640–58.
22. Zhang X, Cheng H, Bao Y, Tang F, Wang Y. diagnostic value of STAT6 expression in thyroid lesions. Acta Endocrinol (Copenhagen). 2018;218(2):164–214.
23. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sun SG, Chen CL, Zhang L, Wang R, Su F, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumors. J Pathol. 2015;452(2):39–50.
24. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sun SG, Chen CL, Zhang L, Wang R, Su F, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumors. J Pathol. 2015;452(2):39–50.
25. Chilosi M, Facchetti F, Deli Tos AP, Lestani M, Morassi ML, Martignoni G, Soro C, Benedetti A, Morelli L, Doglioni C, et al. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol. 1997;181(4):362–7.
26. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol. 1998;22(7):863–72.
27. Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auxilair D, McKenna A, Heinrich MC, Frank DA, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45(2):131–2.
28. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sun SG, Chen CL, Zhang L, Wang R, Su F, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumors. J Pathol. 2015;452(2):39–50.
29. Yoshida A, Tsuta K, Ohno M, Yoshida M, Narita Y, Kawai A, Asahuma H, RITApopp K. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol. 2014;38(4):552–9.
30. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick J. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27(3):390–404.
31. Zhang X, Cheng H, Bao Y, Tang F, Wang Y. diagnostic value of STAT6 expression in thyroid lesions. Acta Endocrinol (Copenhagen). 2018;218(2):164–214.
32. Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ, Brennan MF, Coit DG. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057–68.
33. Chen CL, Zhang L, Wang R, Su F, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumors. J Pathol. 2015;452(2):39–50.
34. England DM, Holzholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13(8):640–58.
35. van Houdt WJ, Westerveld CM, Wijnenhoek JE, van Gorp J, van Coevorden F, Verhoeft C, van Dalen T. Prognosis of solitary fibrous tumors: a multicenter study. Ann Surg Oncol. 2013;20(13):4090–5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.